207 related articles for article (PubMed ID: 1450072)
21. Long-term risk of second malignancy after treatment of Hodgkin's disease: the influence of treatment, age and follow-up time.
Foss Abrahamsen A; Andersen A; Nome O; Jacobsen AB; Holte H; Foss Abrahamsen J; Kvaløy S
Ann Oncol; 2002 Nov; 13(11):1786-91. PubMed ID: 12419752
[TBL] [Abstract][Full Text] [Related]
22. Second malignancies following testicular cancer, ovarian cancer and Hodgkin's disease: an international collaborative study among cancer registries.
Kaldor JM; Day NE; Band P; Choi NW; Clarke EA; Coleman MP; Hakama M; Koch M; Langmark F; Neal FE
Int J Cancer; 1987 May; 39(5):571-85. PubMed ID: 3570550
[TBL] [Abstract][Full Text] [Related]
23. Hodgkin's disease: subsequent primary cancers in relation to treatment.
Prior P; Pope DJ
Br J Cancer; 1988 Oct; 58(4):512-7. PubMed ID: 3207608
[TBL] [Abstract][Full Text] [Related]
24. Second malignant tumours in childhood Hodgkin's disease.
Jenkin D; Greenberg M; Fitzgerald A
Med Pediatr Oncol; 1996 Jun; 26(6):373-9. PubMed ID: 8614372
[TBL] [Abstract][Full Text] [Related]
25. Free-from-failure survival in Hodgkin's disease. Long-term analysis of 148 cases treated with a MOPP-modified protocol.
Silingardi V; Federico M; Frassoldati A; Barbieri F; Palomba G; Mauri C
Acta Haematol; 1989; 82(4):179-86. PubMed ID: 2511719
[TBL] [Abstract][Full Text] [Related]
26. Risk of second primary cancer after Hodgkin's disease in patients in the British National Lymphoma Investigation: relationships to host factors, histology and stage of Hodgkin's disease, and splenectomy.
Swerdlow AJ; Douglas AJ; Vaughan Hudson G; Vaughan Hudson B; MacLennan KA
Br J Cancer; 1993 Nov; 68(5):1006-11. PubMed ID: 8217588
[TBL] [Abstract][Full Text] [Related]
27. [Hodgkin's lymphoma and secondary leukemias].
Centurioni R; Brianzoni MF; Salvi A; Montillo M; Rupoli S; Olivieri A; Leoni P; Danieli G
Recenti Prog Med; 1993 May; 84(5):328-35. PubMed ID: 8511392
[TBL] [Abstract][Full Text] [Related]
28. Breast cancer in Hodgkin's disease and non-Hodgkin's lymphoma survivors.
Sanna G; Lorizzo K; Rotmensz N; Bagnardi V; Cinieri S; Colleoni M; Nolè F; Goldhirsch A
Ann Oncol; 2007 Feb; 18(2):288-92. PubMed ID: 17088328
[TBL] [Abstract][Full Text] [Related]
29. Hodgkin's disease: summary of twenty years' experience.
Mazza P; Bocchia M; Zinzani PL; Fiacchini M; Gherlinzoni F; Bandini G; Bendandi M; Frezza GP; Neri S; Barbieri E
Haematologica; 1992; 77(6):487-93. PubMed ID: 1283856
[TBL] [Abstract][Full Text] [Related]
30. Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood.
van Leeuwen FE; Klokman WJ; Veer MB; Hagenbeek A; Krol AD; Vetter UA; Schaapveld M; van Heerde P; Burgers JM; Somers R; Aleman BM
J Clin Oncol; 2000 Feb; 18(3):487-97. PubMed ID: 10653864
[TBL] [Abstract][Full Text] [Related]
31. Skin cancer and non-Hodgkin's lymphoma as second malignancies. markers of impaired immune function?
Hemminki K; Jiang Y; Steineck G
Eur J Cancer; 2003 Jan; 39(2):223-9. PubMed ID: 12509955
[TBL] [Abstract][Full Text] [Related]
32. Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV).
Wheeler C; Khurshid A; Ibrahim J; Elias A; Mauch P; Ault K; Antin J
Leuk Lymphoma; 2001 Feb; 40(5-6):499-509. PubMed ID: 11426523
[TBL] [Abstract][Full Text] [Related]
33. High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
Harrison CN; Gregory W; Hudson GV; Devereux S; Goldstone AH; Hancock B; Winfield D; MacMillan AK; Hoskin P; Newland AC; Milligan D; Linch DC
Br J Cancer; 1999 Oct; 81(3):476-83. PubMed ID: 10507773
[TBL] [Abstract][Full Text] [Related]
34. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
[TBL] [Abstract][Full Text] [Related]
35. Increased risk of second cancers in managing Hodgkins disease: the 20-year Leiden experience.
Sont JK; van Stiphout WA; Noordijk EM; Molenaar J; Zwetsloot-Schonk JH; Willemze R; Vandenbroucke JP
Ann Hematol; 1992 Nov; 65(5):213-8. PubMed ID: 1457578
[TBL] [Abstract][Full Text] [Related]
36. Second cancers among long-term survivors of Hodgkin's disease diagnosed in childhood and adolescence.
Metayer C; Lynch CF; Clarke EA; Glimelius B; Storm H; Pukkala E; Joensuu T; van Leeuwen FE; van't Veer MB; Curtis RE; Holowaty EJ; Andersson M; Wiklund T; Gospodarowicz M; Travis LB
J Clin Oncol; 2000 Jun; 18(12):2435-43. PubMed ID: 10856104
[TBL] [Abstract][Full Text] [Related]
37. Italian cancer figures--Report 2015: The burden of rare cancers in Italy.
; Busco S; Buzzoni C; Mallone S; Trama A; Castaing M; Bella F; Amodio R; Bizzoco S; Cassetti T; Cirilli C; Cusimano R; De Angelis R; Fusco M; Gatta G; Gennaro V; Giacomin A; Giorgi Rossi P; Mangone L; Mannino S; Rossi S; Pierannunzio D; Tavilla A; Tognazzo S; Tumino R; Vicentini M; Vitale MF; Crocetti E; Dal Maso L
Epidemiol Prev; 2016; 40(1 Suppl 2):1-120. PubMed ID: 26951748
[TBL] [Abstract][Full Text] [Related]
38. [Second neoplasms as a late complication of the treatment of Hodgkin's disease].
Morales MD; González FA; Villegas A; del Potro E; Díaz Mediavilla J; Martínez R; Alvarez A; Colomé JA
Sangre (Barc); 1992 Dec; 37(6):429-33. PubMed ID: 1293793
[TBL] [Abstract][Full Text] [Related]
39. Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma.
Schaapveld M; Aleman BM; van Eggermond AM; Janus CP; Krol AD; van der Maazen RW; Roesink J; Raemaekers JM; de Boer JP; Zijlstra JM; van Imhoff GW; Petersen EJ; Poortmans PM; Beijert M; Lybeert ML; Mulder I; Visser O; Louwman MW; Krul IM; Lugtenburg PJ; van Leeuwen FE
N Engl J Med; 2015 Dec; 373(26):2499-511. PubMed ID: 26699166
[TBL] [Abstract][Full Text] [Related]
40. Treatment of advanced-stage massive mediastinal Hodgkin's disease: the case for combined modality treatment.
Longo DL; Russo A; Duffey PL; Hubbard SM; Glatstein E; Hill JB; Jaffe ES; Young RC; DeVita VT
J Clin Oncol; 1991 Feb; 9(2):227-35. PubMed ID: 1988570
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
